Delving into the Latest Updates on IMA-970A with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine

Synonyms

Cancer Vaccine, HepaVac-101 vaccine, Hepatocellular carcinoma vaccine

+ [2]

Target-

Mechanism

Immunostimulants

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication

Hepatocellular Carcinoma

Inactive Indication-

Originator Organization

Fondazione Irccs Istituto Nazionale Dei Tumori

Active Organization

CureVac SEUniversity Of InsurbiaFondazione Irccs Istituto Nazionale Dei Tumori

+ [2]

Inactive Organization

CureVac NV

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The trial is designed as a single-arm, open-label, phase I study investigating an off-the-shelf, multi-peptide-base HCC vaccine plus Montanide, combined with Durvalumab in patients with very early, early and intermediate stage of HCC. The investigational agents will be applied without concomitant anti-tumour therapy with the intention to reduce risk of recurrence/progression in patients who have received all indicated standard treatments.

Start Date22 Nov 2022

Sponsor / Collaborator

National Cancer Institute

NCT03203005 / CompletedPhase 1/2IIT

A Phase I/II Trial of IMA970A Plus CV8102 Following a Single Pre-vaccination Infusion of Cyclophosphamide in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments

This study is being carried out in order to evaluate a new cancer vaccine called IMA970A combined with CV8102, a new adjuvant for the treatment of liver cancer (hepatocellular carcinoma). It will be investigated whether IMA970A and CV8102 is safe and can trigger an immune response against the tumor, which may prevent the tumor (cancer) from recurring or spreading or may even lead to tumor shrinkage following the standard treatments the patients have previously received.

Start Date18 Sep 2017

Sponsor / Collaborator

National Cancer Institute

[+2]

JPRN-UMIN000004664 / RecruitingPhase 1/2IIT

Cancer Vaccine Therapy using Gene of antigen related to new cancer origin Epitope Peptide Restricted to HLA-A24 in Patients with Hepatocellular carcinoma(Phase 1/2 study). - Cancer Vaccine Therapy using Epitope Peptide Restricted to HLA-A24 in Patients with Hepatocellular carcinoma(Phase1/2 study).

Start Date01 Dec 2010

Sponsor / Collaborator-

100 Clinical Results associated with IMA-970A

Login to view more data

100 Translational Medicine associated with IMA-970A

Login to view more data

100 Patents (Medical) associated with IMA-970A

Login to view more data

202

Literatures (Medical) associated with IMA-970A

19 Aug 2024·ACS Applied Bio Materials

Lipid- and Polymer-Based Nanocarrier Platforms for Cancer Vaccine Delivery

Review

Author: Abujaber, Razan ; Sunoqrot, Suhair ; Al-Majawleh, May ; Talhouni, Shahd ; Abdel Gaber, Sara A

Cancer immunotherapy has gained popularity in recent years in the search for effective treatment modalities for various malignancies, particularly those that are resistant to conventional chemo- and radiation therapy. Cancer vaccines target the cancer-immunity cycle by boosting the patient's own immune system to recognize and kill cancer cells, thus serving as both preventative and curative therapeutic tools. Among the different types of cancer vaccines, those based on nanotechnology have shown great promise in advancing the field of cancer immunotherapy. Lipid-based nanoparticles (NPs) have become the most advanced platforms for cancer vaccine delivery, but polymer-based NPs have also received considerable interest. This Review aims to provide an overview of the nanotechnology-enabled cancer vaccine landscape, focusing on recent advances in lipid- and polymer-based nanovaccines and their hybrid structures and discussing the challenges against the clinical translation of these important nanomedicines.

13 Aug 2024·Blood Advances

Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma

Article

Author: Frenkel, Felix ; Kahl, Brad S ; Desai, Sweta ; Schreiber, Robert D ; Russler-Germain, David A ; Krysiak, Kilannin ; Griffith, Malachi ; Bagaev, Alexander ; Mooney, Thomas B ; Kiwala, Susanna ; Cashen, Amanda F ; Belousov, Vladislav ; Ramirez, Cody A ; Schappe, Timothy ; Kudryashova, Olga ; Ocheredko, Elena ; Griffith, Obi L ; Ataullakhanov, Ravshan ; Walker, Jason R ; Watkins, Marcus P ; Fronick, Catrina C ; Becker-Hapak, Michelle ; Hundal, Jasreet ; Mehta-Shah, Neha ; Singhal, Kartik ; Bartlett, Nancy L ; Barnell, Erica K ; Gomez, Felicia ; McClain, Ethan D ; Fulton, Robert S ; Skidmore, Zachary L ; Onyeador, Onyinyechi C ; Fehniger, Todd A

AbstractPersonalized cancer vaccines designed to target neoantigens represent a promising new treatment paradigm in oncology. In contrast to classical idiotype vaccines, we hypothesized that “polyvalent” vaccines could be engineered for the personalized treatment of follicular lymphoma (FL) using neoantigen discovery by combined whole-exome sequencing (WES) and RNA sequencing (RNA-seq). Fifty-eight tumor samples from 57 patients with FL underwent WES and RNA-seq. Somatic and B-cell clonotype neoantigens were predicted and filtered to identify high-quality neoantigens. B-cell clonality was determined by the alignment of B-cell receptor (BCR) CDR3 regions from RNA-seq data, grouping at the protein level, and comparison with the BCR repertoire from healthy individuals using RNA-seq data. An average of 52 somatic mutations per patient (range, 2-172) were identified, and ≥2 (median, 15) high-quality neoantigens were predicted for 56 of 58 FL samples. The predicted neoantigen peptides were composed of missense mutations (77%), indels (9%), gene fusions (3%), and BCR sequences (11%). Building off of these preclinical analyses, we initiated a pilot clinical trial using personalized neoantigen vaccination combined with PD-1 blockade in patients with relapsed or refractory FL (#NCT03121677). Synthetic long peptide vaccines targeting predicted high-quality neoantigens were successfully synthesized for and administered to all 4 patients enrolled. Initial results demonstrate feasibility, safety, and potential immunologic and clinical responses. Our study suggests that a genomics-driven personalized cancer vaccine strategy is feasible for patients with FL, and this may overcome prior challenges in the field. This trial was registered at www.ClinicalTrials.gov as #NCT03121677.

01 Jul 2024·International Journal of Pharmaceutics

Nanobody-liposomes as novel cancer vaccine platform to efficiently stimulate T cell immunity

Article

Author: Olesek, K ; Affandi, A J ; Heukers, R ; Nijen Twilhaar, M K ; Metselaar, J M ; Kalay, H ; Ambrosini, M ; Bouma, R G ; van Dommelen, J M A ; van Rooijen, A ; den Haan, J M M ; de Haas, A M ; Oliveira, S ; van Kooyk, Y ; Mesquita, B S ; Storm, G ; Brink, H J

Cancer vaccines can be utilized in combination with checkpoint inhibitors to optimally stimulate the anti-tumor immune response. Uptake of vaccine antigen by antigen presenting cells (APCs) is a prerequisite for T cell priming, but often relies on non-specific mechanisms. Here, we have developed a novel vaccination strategy consisting of cancer antigen-containing liposomes conjugated with CD169- or DC-SIGN-specific nanobodies (single domain antibodies) to achieve specific uptake by APCs. Our studies demonstrate efficient nanobody liposome uptake by human and murine CD169⁺ and DC-SIGN⁺ APCs in vitro and in vivo when compared to control liposomes or liposomes with natural ligands for CD169 and DC-SIGN. Uptake of CD169 nanobody liposomes resulted in increased T cell activation by human APCs and stimulated naive T cell priming in mouse models. In conclusion, while nanobody liposomes have previously been utilized to direct drugs to tumors, here we show that nanobody liposomes can be applied as vaccination strategy that can be extended to other receptors on APCs in order to elicit a potent immune response against tumor antigens.

100 Deals associated with IMA-970A

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatocellular Carcinoma	Phase 2	-	University Of Insurbia	-
Hepatocellular Carcinoma	Phase 2	-	Fondazione Irccs Istituto Nazionale Dei Tumori	-
Hepatocellular Carcinoma	Phase 2	-	Immatics Biotechnologies GmbH	-
Hepatocellular Carcinoma	Phase 2	-	CureVac SE	-
Hepatocellular Carcinoma	Phase 2	-	Universitaetsklinikum Tuebingen	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03203005 (Pubmed \| Clin Cancer Res) Manual	Phase 1/2	Hepatocellular Carcinoma	22	Cyclophosphamide+IMA 970 A+CV 8102	ygcclliylk(ihsudogvdg) = against ≥1 vaccinated HLA class I tumor-associated peptide (TAA) and ≥1 vaccinated HLA class II TAA were respectively induced in 37% and 53% of the vaccinees khcvpvcavr (fzpgjhekcu ) View more	Positive	13 Jun 2022